NSI-189
Experimental neurogenic compound evaluated for major depressive disorder. The phase 2 primary clinician-rated depression outcome was not significantly better than placebo, despite signals on some secondary patient-reported and cognitive measures.
Pharmacokinetic model
A route-level PK model for nsi-189 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Investigational Nootropic
- Suggested cadence
- once daily
Research behind this entry
-
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder
In 220 adults, neither 40 nor 80 mg/day produced a significant benefit on the prespecified clinician-rated primary depression endpoint. Some secondary measures favored treatment, making the overall result mixed rather…
-
The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects
Narrative review summarized early development and proposed neurogenic, cognitive, and antidepressant effects before the later phase 2 result. It is not independent confirmation of efficacy.
2 published studies referenced in the app, each with a plain-language summary.